ISPC (iSpecimen) Return-on-Tangible-Asset: -164.93% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISPC iSpecimen Inc ISPC
48 GF Score
Price $2.39
GF Value $6.65
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is iSpecimen Return-on-Tangible-Asset?

iSpecimen ISPC +2.14% 48 Return-on-Tangible-Asset is -164.93% as of Mar. 2026. GuruFocus rates ISPC with a GF Score™ of 48/100 and a GF Value™ of $6.65 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, iSpecimen ranks worse than 96.71% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. iSpecimen's annualized Net Income for the quarter that ended in Mar. 2026 was $-9.10 Mil. iSpecimen's average total tangible assets for the quarter that ended in Mar. 2026 was $5.52 Mil. Therefore, iSpecimen's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -164.93%.

The historical rank and industry rank for iSpecimen's Return-on-Tangible-Asset or its related term are showing as below:

ISPC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -301.02   Med: -177.79   Max: -38.57
Current: -301.02

During the past 8 years, iSpecimen's highest Return-on-Tangible-Asset was -38.57%. The lowest was -301.02%. And the median was -177.79%.

ISPC's Return-on-Tangible-Asset is ranked worse than
96.71% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.25 vs ISPC: -301.02

iSpecimen  (NAS:ISPC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


iSpecimen Return-on-Tangible-Asset Related Terms


iSpecimen Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for iSpecimen's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iSpecimen Return-on-Tangible-Asset Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial -48.99 -38.57 -77.34 -198.24 -185.92

iSpecimen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.89 -241.52 -406.06 -357.15 -164.93

ISPC vs BIAF, FUNI, IVRO: Return-on-Tangible-Asset Comparison

For the Diagnostics & Research subindustry, iSpecimen's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iSpecimen Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where iSpecimen's Return-on-Tangible-Asset falls into.


ISPC
48GF Score
iSpecimen Inc ISPC
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iSpecimen Return-on-Tangible-Asset Calculation

iSpecimen's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-10.488/( (4.021+7.261)/ 2 )
=-10.488/5.641
=-185.92 %

iSpecimen's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-9.1/( (7.261+3.774)/ 2 )
=-9.1/5.5175
=-164.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -164.93% mean?
iSpecimen (ISPC) has a Return-on-Tangible-Asset of -164.93% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on iSpecimen and its competitors. According to the industry distribution chart, iSpecimen ranks #206 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 96.7%.
Is iSpecimen's Return-on-Tangible-Asset too high?
iSpecimen's current Return-on-Tangible-Asset is -164.93%. Based on the distribution chart, iSpecimen ranks #206 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, iSpecimen has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does iSpecimen's Return-on-Tangible-Asset compare to BIAF and FUNI?
According to the Medical Diagnostics & Research industry distribution chart, iSpecimen ranks #206 out of 213 companies for Return-on-Tangible-Asset. This places iSpecimen in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on iSpecimen and its competitors. iSpecimen's current Return-on-Tangible-Asset is -164.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iSpecimen stock overvalued right now?
Based on GuruFocus' analysis, iSpecimen (ISPC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.65, compared to a current price of $2.39 — trading 64.1% below its estimated fair value. The current Return-on-Tangible-Asset is -164.93%. iSpecimen's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For iSpecimen (ISPC), the current Return-on-Tangible-Asset is -164.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iSpecimen (ISPC) Overvalued in 2026?

Based on GuruFocus' analysis, iSpecimen stock appears to be undervalued. The current stock price of $2.39 is trading 64.1% below its estimated GF Value™ of $6.65. GuruFocus considers iSpecimen to be Possible Value Trap.

Key valuation signals for ISPC:

  • Return-on-Tangible-Asset: -164.93%
  • GF Value™: $6.65 vs. price of $2.39 (64.1% below fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the ISPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iSpecimen Business Description

Address 8 Cabot Road, Suite 1800, Woburn, MA, USA, 01801
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
48GF Score

Get the complete analysis for ISPC

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.39
Price
$6.65
GF Value